Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug boost heart surgery success?

NCT ID NCT07331727

Disease control Sponsor: Shanghai Chest Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests whether dapagliflozin, a drug typically used for diabetes, can reduce the return of atrial fibrillation after a heart ablation procedure. The study focuses on patients with persistent AF and increased epicardial adipose tissue (heart fat), which is linked to higher recurrence risk. About 280 participants will receive either dapagliflozin or standard care for 3 months after ablation. The main goal is to see if the drug lowers the amount of time spent in atrial arrhythmia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dapagliflozin (a diabetes drug that may also reduce heart fat and inflammation)
What this could lead to
If it works, this could offer a new way to improve ablation success in persistent atrial fibrillation patients with excess heart fat.
What could go wrong
This is an early-stage trial with no phase assigned, so results are uncertain. The drug may not reduce recurrence, and side effects like dehydration or urinary infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 280 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-80 years; Diagnosis of persistent atrial fibrillation (continuous AF \>7 days and ≤5 years); Planned first-time catheter ablation for AF; No class I indications for dapagliflozin, defined as: No diabetes mellitus; No history of heart failure (HFrEF, HFmrEF, or HFpEF); No chronic kidney disease (eGFR ≥60 mL/min/1.73 m²); Evidence of increased epicardial adipose tissue on cardiac CT or cardiac MRI, defined according to pre-specified imaging thresholds; Ability to provide written informed consent. Exclusion Criteria: * Duration of persistent AF \>5 years; Left atrial anteroposterior diameter \>50 mm on transthoracic echocardiography; Prior AF catheter ablation or surgical ablation; Current or recent (within 3 months) use of any SGLT2 inhibitor; Severe structural heart disease (e.g., hypertrophic cardiomyopathy, rheumatic valvular disease, dilated cardiomyopathy); Contraindications to catheter ablation (e.g., left atrial thrombus, active infection); Estimated glomerular filtration rate \<60 mL/min/1.73 m²; Type 1 diabetes or history of diabetic ketoacidosis; Pregnancy or breastfeeding; Any condition deemed by investigators to make study participation inappropriate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shanghai Chest Hospital

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.